IASLC 20th World Conference on Lung Cancer: Independent satellite symposium
Chaired by Corey Langer with Enriqueta Felip, David Heigener and Myung-Ju Ahn
This independent symposium, led by an expert international faculty, discussed treatment choices for non-small-cell lung cancer (NSCLC) without targetable mutations, surveying current standards in care against the latest clinical trial data.
Symposium learning objectives
The aim of the symposium was to enable participants to:
- Utilize the latest regional recommendations and guidelines in clinical practice for first- and subsequent-line treatment of NSCLC without an actionable driver
- Evaluate the most recent trial data on emerging treatments and combinations, and explain where and how these options may enhance the current landscape
- Explain how to identify hyperprogressive disease and its influence on treatment decisions
Faculty videos
Our experts summarize their presentations in the symposium:
Read Dr Langer's full bio here
Read Dr Felip's full bio here
Read Dr Heigener's full bio here
Read Dr Ahn's full bio here
Accreditation
This symposium has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credit (ECMEC®). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Target audience
The symposium and enduring materials are targeted at international (medical and radiation) oncologists and any other healthcare professionals involved in the diagnosis, treatment and follow-up of patients with lung cancer.
Educational grant
This activity is supported by an education grant from Eli Lilly and Company.
Contact us
Springer Healthcare IME.
Email: IME@springer.com
Telephone +44 (0) 203 192 2023
Springer Healthcare IME
The Campus, 4 Crinan Street
London, N1 9XW, UK